Engimmune Therapeutics

Investment area
Novo Seeds
Date of investment
May 2022

Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T cell receptor (TCR) therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. Spinning out from ETH Zurich and with support from BaseLaunch, the Swiss life sciences incubator, the Company raised a CHF 15.5 million seed series from leading biotech investors, Pureos Bioventures and Novo Holdings

Engimmune Therapeutics

Investment area
Novo Seeds
Date of investment
May 2022

Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T cell receptor (TCR) therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. Spinning out from ETH Zurich and with support from BaseLaunch, the Swiss life sciences incubator, the Company raised a CHF 15.5 million seed series from leading biotech investors, Pureos Bioventures and Novo Holdings

Engimmune Therapeutics

Investment area
Novo Seeds
Date of investment
May 2022

Engimmune Therapeutics is a technology platform and product-based company using cutting-edge technologies to engineer highly potent and specific T cell receptor (TCR) therapies. By applying proprietary platform technologies combining genome editing, functional high-throughput screening, deep sequencing and machine learning, Engimmune addresses key efficacy and safety challenges that currently limit the full potential of TCR-T cell and soluble TCR therapeutics. Spinning out from ETH Zurich and with support from BaseLaunch, the Swiss life sciences incubator, the Company raised a CHF 15.5 million seed series from leading biotech investors, Pureos Bioventures and Novo Holdings